No Data
No Data
Eterna Therapeutics Changes Name to Ernexa Therapeutics
Express News | Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
Eterna Therapeutics | 10-K: FY2024 Annual Report
Eterna Therapeutics Announces Inaugural Scientific Advisory Board Meeting, Discussed ERNA-101 Preclinical Advances In Ovarian Cancer, Focused On Immune Activation, Tumor Microenvironment, Combination Therapies, And ERNA-102 For Autoimmune Diseases
Express News | Eterna Therapeutics Announces Expansion of Scientific Advisory Board
Press Release: Eterna Therapeutics Announces Expansion of Scientific Advisory Board
Unlock the Full List